PsyRING's neuroscience expertise makes us uniquely placed to exploit emerging knowledge of the biological basis of psychiatric and neurological disease, for target gene identification, selection and validation.
This allows the optimal genetic sites for therapeutic intervention in a complex and multi-factorial disease to be identified and validated.
Through the existing sample collection (~1000) of control and schizophrenia blood samples, PsyRING is able to offer SNP analysis on genes of interest.
PsyRING can carry out similar studies for a range of other psychiatric diseases in addition to schizophrenia (e.g. bipolar disorder, major depression, autism).